Eli Lilly and Company (LLY)vsPro-Dex Inc (PDEX)
LLY
Eli Lilly and Company
$1,131.42
-0.26%
HEALTHCARE · Cap: $948.95B
PDEX
Pro-Dex Inc
$67.00
+2.81%
HEALTHCARE · Cap: $207.53M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 96701% more annual revenue ($72.25B vs $74.64M). LLY leads profitability with a 35.0% profit margin vs 16.1%. PDEX trades at a lower P/E of 17.9x. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
PDEX
Buy57
out of 100
Grade: C
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Safe zone — low bankruptcy risk
Every $100 of equity generates 27 in profit
Attractively priced relative to earnings
Earnings expanding 22.4% YoY
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 32.4x book value
Smaller company, higher risk/reward
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : PDEX
The strongest argument for PDEX centers on Altman Z-Score, Return on Equity, P/E Ratio. Profitability is solid with margins at 16.1% and operating margin at 15.5%. Revenue growth of 14.6% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book.
Bear Case : PDEX
The primary concerns for PDEX are Market Cap.
Key Dynamics to Monitor
LLY profiles as a growth stock while PDEX is a mature play — different risk/reward profiles.
LLY carries more volatility with a beta of 0.48 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 57/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Pro-Dex Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Pro-Dex, Inc. designs, develops and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company is headquartered in Irvine, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?